{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T02:05:01Z","timestamp":1795140301263,"version":"4.10.3"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T00:00:00Z","timestamp":1718755200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T00:00:00Z","timestamp":1718755200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>This phase II trial aimed to determine the efficacy and safety of induction chemoimmunotherapy of camrelizumab plus modified TPF in locally advanced hypopharyngeal squamous cell carcinoma (LA HSCC) (NCT04156698). The primary endpoint was objective response rate (ORR), and secondary endpoints were 3-year overall survival (OS), progression-free survival (PFS), larynx preservation rate (LPR), and metastasis-free survival (MFS). Patients (cT3-4aN0-2M0), regardless of sex, received induction chemoimmunotherapy for three cycles: camrelizumab 200\u2009mg d1, docetaxel 75\u2009mg\/m<jats:sup>2<\/jats:sup> d1, cisplatin 25\u2009mg\/m<jats:sup>2<\/jats:sup> d1-3, and capecitabine 800\u2009mg\/m<jats:sup>2<\/jats:sup> bid d1-14, q21d. Patients were assigned to radioimmunotherapy if they had a complete or partial response, those with stable or progressive disease underwent surgery and adjuvant (chemo)radiotherapy. Camrelizumab was maintained post-radioimmunotherapy. Fifty-one patients were enrolled with a median follow-up duration of 23.7 months. After induction therapy, the ORR was 82.4% (42\/51), meeting the prespecified endpoint. Grade 3\/4 adverse events occurred in 26 patients, and no treatment-related death occurred. As three-year outcomes were immature, two-year OS, PFS and LPR were reported. As no distant metastatic event had occurred, MFS was not reported here. The two-year OS, PFS, and LPR rates were 83.0%, 77.1%, and 70.0%, respectively. The induction chemoimmunotherapy of camrelizumab plus TPF showed a high ORR rate with an acceptable safety profile in LA HSCC.<\/jats:p>","DOI":"10.1038\/s41467-024-49121-3","type":"journal-article","created":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T15:01:59Z","timestamp":1718809319000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Camrelizumab-based induction chemoimmunotherapy in locally advanced stage hypopharyngeal carcinoma: phase II clinical trial"],"prefix":"10.1038","volume":"15","author":[{"given":"Hongli","family":"Gong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohui","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Heng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengzhi","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunping","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengzi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8588-2959","authenticated-orcid":false,"given":"Liang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,19]]},"reference":[{"key":"49121_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209\u2013249 (2021).","journal-title":"CA Cancer J. Clin."},{"key":"49121_CR2","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1056\/NEJMra1715715","volume":"382","author":"LQM Chow","year":"2020","unstructured":"Chow, L. Q. M. Head and Neck Cancer. N. Engl. J. Med. 382, 60\u201372 (2020).","journal-title":"N. Engl. J. Med."},{"key":"49121_CR3","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1200\/JCO.2012.43.6097","volume":"31","author":"AA Forastiere","year":"2013","unstructured":"Forastiere, A. A. et al. Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. J. Clin. Oncol. 31, 845\u2013852 (2013).","journal-title":"J. Clin. Oncol."},{"key":"49121_CR4","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1093\/annonc\/mdy102","volume":"29","author":"RI Haddad","year":"2018","unstructured":"Haddad, R. I. et al. Induction chemotherapy in locally advanced squamous cell carcinoma of the head and neck: role, controversy, and future directions. Ann. Oncol. 29, 1130\u20131140 (2018).","journal-title":"Ann. Oncol."},{"key":"49121_CR5","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/S1470-2045(21)00076-0","volume":"22","author":"C Petit","year":"2021","unstructured":"Petit, C. et al. Chemotherapy and radiotherapy in locally advanced head and neck cancer: an individual patient data network meta-analysis. Lancet Oncol. 22, 727\u2013736 (2021).","journal-title":"Lancet Oncol."},{"key":"49121_CR6","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","volume":"375","author":"RL Ferris","year":"2016","unstructured":"Ferris, R. L. et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 375, 1856\u20131867 (2016).","journal-title":"N. Engl. J. Med."},{"key":"49121_CR7","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/S1470-2045(16)30066-3","volume":"17","author":"TY Seiwert","year":"2016","unstructured":"Seiwert, T. Y. et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol. 17, 956\u2013965 (2016).","journal-title":"Lancet Oncol."},{"key":"49121_CR8","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/S0140-6736(18)31999-8","volume":"393","author":"EEW Cohen","year":"2019","unstructured":"Cohen, E. E. W. et al. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Lancet 393, 156\u2013167 (2019).","journal-title":"Lancet"},{"key":"49121_CR9","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1016\/S1470-2045(18)30495-9","volume":"19","author":"W Fang","year":"2018","unstructured":"Fang, W. et al. Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials. Lancet Oncol. 19, 1338\u20131350 (2018).","journal-title":"Lancet Oncol."},{"key":"49121_CR10","doi-asserted-by":"publisher","first-page":"e404","DOI":"10.1016\/S1470-2045(19)30306-7","volume":"20","author":"SD Karam","year":"2019","unstructured":"Karam, S. D. & Raben, D. Radioimmunotherapy for the treatment of head and neck cancer. Lancet Oncol. 20, e404\u2013e416 (2019).","journal-title":"Lancet Oncol."},{"key":"49121_CR11","unstructured":"Machiels, J. P. et al. Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial. Lancet Oncol. 25, 572\u2013587 (2024)."},{"key":"49121_CR12","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.annonc.2022.10.006","volume":"34","author":"Y Tao","year":"2022","unstructured":"Tao, Y. et al. Pembrolizumab versus cetuximab concurrent with radiotherapy in patients with locally advanced squamous cell carcinoma of head and neck unfit for cisplatin (GORTEC 2015-01 PembroRad): a multicenter, randomized, phase II trial. Ann. Oncol. 34, 101\u2013110 (2022).","journal-title":"Ann. Oncol."},{"key":"49121_CR13","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/S1470-2045(20)30737-3","volume":"22","author":"NY Lee","year":"2021","unstructured":"Lee, N. Y. et al. Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. Lancet Oncol. 22, 450\u2013462 (2021).","journal-title":"Lancet Oncol."},{"key":"49121_CR14","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1200\/JCO.20.00290","volume":"39","author":"S McBride","year":"2021","unstructured":"McBride, S. et al. Randomized phase II trial of nivolumab with stereotactic body radiotherapy versus nivolumab alone in metastatic head and neck squamous cell carcinoma. J. Clin. Oncol. 39, 30\u201337 (2021).","journal-title":"J. Clin. Oncol."},{"key":"49121_CR15","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1001\/jamaoto.2021.2191","volume":"147","author":"R Masarwy","year":"2021","unstructured":"Masarwy, R., Kampel, L., Horowitz, G., Gutfeld, O. & Muhanna, N. Neoadjuvant PD-1\/PD-L1 inhibitors for resectable head and neck cancer: a systematic review and meta-analysis. JAMA Otolaryngol. Head. Neck Surg. 147, 871\u2013878 (2021).","journal-title":"JAMA Otolaryngol. Head. Neck Surg."},{"key":"49121_CR16","doi-asserted-by":"publisher","first-page":"3268","DOI":"10.1158\/1078-0432.CCR-22-0666","volume":"28","author":"Z Zhang","year":"2022","unstructured":"Zhang, Z. et al. Neoadjuvant chemoimmunotherapy for the treatment of locally advanced head and neck squamous cell carcinoma: a single-arm phase 2 clinical trial. Clin. Cancer Res 28, 3268\u20133276 (2022).","journal-title":"Clin. Cancer Res"},{"key":"49121_CR17","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1038\/s43018-022-00450-6","volume":"3","author":"LB Darragh","year":"2022","unstructured":"Darragh, L. B. et al. A phase I\/Ib trial and biological correlate analysis of neoadjuvant SBRT with single-dose durvalumab in HPV-unrelated locally advanced HNSCC. Nat. Cancer 3, 1300\u20131317 (2022).","journal-title":"Nat. Cancer"},{"key":"49121_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-33080-8","volume":"13","author":"WT Ju","year":"2022","unstructured":"Ju, W. T. et al. A pilot study of neoadjuvant combination of anti-PD-1 camrelizumab and VEGFR2 inhibitor apatinib for locally advanced resectable oral squamous cell carcinoma. Nat. Commun. 13, 5378 (2022).","journal-title":"Nat. Commun."},{"key":"49121_CR19","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1158\/1078-0432.CCR-21-3351","volume":"28","author":"TM Wise-Draper","year":"2022","unstructured":"Wise-Draper, T. M. et al. Phase II clinical trial of neoadjuvant and adjuvant pembrolizumab in resectable local-regionally advanced head and neck squamous cell carcinoma. Clin. Cancer Res 28, 1345\u20131352 (2022).","journal-title":"Clin. Cancer Res"},{"key":"49121_CR20","doi-asserted-by":"crossref","unstructured":"Ou, X. et al. Induction Toripalimab and chemotherapy for organ preservation in locally advanced laryngeal and hypopharyngeal cancer: a single-arm phase ii clinical trial. Clin Cancer Res. 30, 344\u2013355 (2024).","DOI":"10.1158\/1078-0432.CCR-23-2398"},{"key":"49121_CR21","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/S1470-2045(10)70279-5","volume":"12","author":"JH Lorch","year":"2011","unstructured":"Lorch, J. H. et al. Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial. Lancet Oncol. 12, 153\u2013159 (2011).","journal-title":"Lancet Oncol."},{"key":"49121_CR22","doi-asserted-by":"publisher","unstructured":"Janoray, G. et al. Long-term results of a multicenter randomized phase iii trial of induction chemotherapy with cisplatin, 5-fluorouracil, +\/- docetaxel for larynx preservation. J. Natl Cancer Inst. 108, https:\/\/doi.org\/10.1093\/jnci\/djv368 (2016).","DOI":"10.1093\/jnci\/djv368"},{"key":"49121_CR23","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1002\/hed.27119","volume":"44","author":"R Li","year":"2022","unstructured":"Li, R. et al. Induction chemotherapy of modified docetaxel, cisplatin, 5-fluorouracil for laryngeal preservation in locally advanced hypopharyngeal squamous cell carcinoma. Head. Neck 44, 2018\u20132029 (2022).","journal-title":"Head. Neck"},{"key":"49121_CR24","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","volume":"394","author":"B Burtness","year":"2019","unstructured":"Burtness, B. et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet 394, 1915\u20131928 (2019).","journal-title":"Lancet"},{"key":"49121_CR25","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1200\/JCO.21.02508","volume":"41","author":"KJ Harrington","year":"2023","unstructured":"Harrington, K. J. et al. Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: updated results of the phase III KEYNOTE-048 study. J. Clin. Oncol. 41, 790\u2013802 (2023).","journal-title":"J. Clin. Oncol."},{"key":"49121_CR26","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1016\/S1470-2045(21)00302-8","volume":"22","author":"Y Yang","year":"2021","unstructured":"Yang, Y. et al. Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 22, 1162\u20131174 (2021).","journal-title":"Lancet Oncol."},{"key":"49121_CR27","doi-asserted-by":"publisher","first-page":"1280208","DOI":"10.3389\/fonc.2023.1280208","volume":"13","author":"Y Lin","year":"2023","unstructured":"Lin, Y. et al. A case report and literature review on reactive cutaneous capillary endothelial proliferation induced by camrelizumab in a nasopharyngeal carcinoma patient. Front. Oncol. 13, 1280208 (2023).","journal-title":"Front. Oncol."},{"key":"49121_CR28","first-page":"e525","volume":"28","author":"Q Ding","year":"2023","unstructured":"Ding, Q. et al. Reactive cutaneous capillary endothelial proliferation predicted the efficacy of camrelizumab in patients with recurrent\/metastatic head and neck squamous cell carcinoma. Med. Oral. Patol. Oral. Cir. Bucal 28, e525\u2013e529 (2023).","journal-title":"Med. Oral. Patol. Oral. Cir. Bucal"},{"key":"49121_CR29","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1158\/1078-0432.CCR-21-4316","volume":"28","author":"AY Deneka","year":"2022","unstructured":"Deneka, A. Y. et al. Association of TP53 and CDKN2A mutation profile with tumor mutation burden in head and neck cancer. Clin. Cancer Res. 28, 1925\u20131937 (2022).","journal-title":"Clin. Cancer Res."},{"key":"49121_CR30","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.1158\/1078-0432.CCR-22-2765","volume":"29","author":"S Wildsmith","year":"2023","unstructured":"Wildsmith, S. et al. Tumor mutational burden as a predictor of survival with durvalumab and\/or tremelimumab treatment in recurrent or metastatic head and neck squamous cell carcinoma. Clin. Cancer Res. 29, 2066\u20132074 (2023).","journal-title":"Clin. Cancer Res."},{"key":"49121_CR31","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1038\/s41591-023-02275-x","volume":"29","author":"NF Saba","year":"2023","unstructured":"Saba, N. F. et al. Pembrolizumab and cabozantinib in recurrent metastatic head and neck squamous cell carcinoma: a phase 2 trial. Nat. Med. 29, 880\u2013887 (2023).","journal-title":"Nat. Med."},{"key":"49121_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-29516-w","volume":"13","author":"C Hoffmann","year":"2022","unstructured":"Hoffmann, C. et al. PD-L1 and ICOSL discriminate human secretory and helper dendritic cells in cancer, allergy and autoimmunity. Nat. Commun. 13, 1983 (2022).","journal-title":"Nat. Commun."}],"updated-by":[{"DOI":"10.1038\/s41467-024-51057-7","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T00:00:00Z","timestamp":1722988800000}}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-49121-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-49121-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-49121-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T06:05:15Z","timestamp":1723097115000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-49121-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,19]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["49121"],"URL":"https:\/\/doi.org\/10.1038\/s41467-024-49121-3","relation":{"correction":[{"id-type":"doi","id":"10.1038\/s41467-024-51057-7","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,19]]},"assertion":[{"value":"14 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2024","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41467-024-51057-7","URL":"https:\/\/doi.org\/10.1038\/s41467-024-51057-7","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5251"}}